Retatrutide vs Mazdutide
Both activate glucagon-related pathways but retatrutide is GIP/GLP-1/glucagon tri-agonist and mazdutide is GLP-1/glucagon dual agonist; development/approval stages differ.
| Attribute | Retatrutide | Mazdutide |
|---|---|---|
| Human evidence | Retatrutide now has peer-reviewed Phase III human evidence in type 2 diabetes (TRANSCEND-T2D-1), alongside earlier randomized Phase II obesity and MASLD data. Obesity Phase III results are also emerging, but published and sponsor-reported evidence should be kept distinct. | Phase 3 GLORY trials show substantial weight loss in Chinese adults. Mazdutide received its first approval in China in June 2025 for long-term weight management and later for type 2 diabetes. |
| Research focus | Obesity, weight management, metabolic disease | Obesity, type 2 diabetes, metabolic liver disease, obstructive sleep apnoea |
| Regulatory status | Not FDA-approved as of this review; FDA states retatrutide has not been found safe and effective for any condition and cannot be used in US compounding. | First approved in China in June 2025 for chronic weight management in qualifying adults; later approved there for glycaemic control in type 2 diabetes. Not a globally authorised medicine. |
| Route / formulation | Evidence applies to trial-grade retatrutide, not to unverified research-market vials or pens. | Clinical evidence concerns regulated trial/authorised subcutaneous formulations. Research-market material cannot be assumed equivalent. |
Why these are compared
These compounds appear in the weight & body composition evidence landscape, but they are not interchangeable. Retatrutide is tri-agonist peptide (gip/glp-1/glucagon receptor agonist) studied in obesity, weight management, metabolic disease; Mazdutide is dual glucagon receptor / glp-1 receptor agonist peptide studied in obesity, type 2 diabetes, metabolic liver disease, obstructive sleep apnoea. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Retatrutide: Multiple Phase 3 human trials; investigational.
Mazdutide: Approved in China for defined indications — jurisdiction specific.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No direct head-to-head outcome trial identified. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.